Background: To explore the impact of patient-characteristics and relevant comorbidities on treatment continuation rates, effectiveness, and satisfaction in patients with erectile dysfunction (ED) who ...
INDIANAPOLIS, Jan 08, 2008 -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Cialis® (tadalafil)(1) for once daily use (2.5 mg and 5 ...
INDIANAPOLIS, July 16, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that study results published in the Journal of Sexual Medicine showed a greater percentage of men who had ...
AgelessRx, a pioneer in longevity and telehealth solutions, announces the launch of its newest offering: Tadalafil Daily, a clinician-directed, low-dose, daily version of a well-known PDE5 inhibitor.
NOTE: After selecting this product, you will need to complete a short assessment, so we can make sure this medication is suitable for you. If approved, our pharmacy team will dispense and dispatch ...
To earn CME related to this news article, click here. April 20, 2009 — Daily administration of the phosphodiesterase type 5 (PDE5) inhibitors tadalafil or sildenafil for 6 months for erectile ...
MIAMI, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that the clinical trial of the Company’s proprietary Tadalafil and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback